vs
Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and HANMI FINANCIAL CORP (HAFC). Click either name above to swap in a different company.
HANMI FINANCIAL CORP is the larger business by last-quarter revenue ($71.2M vs $44.9M, roughly 1.6× AbCellera Biologics Inc.). HANMI FINANCIAL CORP runs the higher net margin — 29.8% vs -19.9%, a 49.8% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 17.1%). HANMI FINANCIAL CORP produced more free cash flow last quarter ($203.7M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 10.4%).
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
Hanmi Bank Corporation is a community bank headquartered in Los Angeles, California, with 35 branches and eight loan production offices in California, Texas, Illinois, New York, New Jersey and Virginia.
ABCL vs HAFC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $44.9M | $71.2M |
| Net Profit | $-8.9M | $21.2M |
| Gross Margin | — | — |
| Operating Margin | -63.7% | 29.8% |
| Net Margin | -19.9% | 29.8% |
| Revenue YoY | 788.4% | 17.1% |
| Net Profit YoY | 73.9% | 20.0% |
| EPS (diluted) | $-0.03 | $0.70 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $44.9M | $71.2M | ||
| Q3 25 | $9.0M | $71.0M | ||
| Q2 25 | $17.1M | $65.2M | ||
| Q1 25 | $4.2M | $62.8M | ||
| Q4 24 | $5.0M | $60.8M | ||
| Q3 24 | $6.5M | $58.5M | ||
| Q2 24 | $7.3M | $56.7M | ||
| Q1 24 | $10.0M | $58.4M |
| Q4 25 | $-8.9M | $21.2M | ||
| Q3 25 | $-57.1M | $22.1M | ||
| Q2 25 | $-34.7M | $15.1M | ||
| Q1 25 | $-45.6M | $17.7M | ||
| Q4 24 | — | $17.7M | ||
| Q3 24 | $-51.1M | $14.9M | ||
| Q2 24 | $-36.9M | $14.5M | ||
| Q1 24 | $-40.6M | $15.2M |
| Q4 25 | -63.7% | 29.8% | ||
| Q3 25 | -851.8% | 31.1% | ||
| Q2 25 | -290.2% | 23.2% | ||
| Q1 25 | -1479.6% | 28.1% | ||
| Q4 24 | — | 29.1% | ||
| Q3 24 | -1439.4% | 25.5% | ||
| Q2 24 | -1276.2% | 25.5% | ||
| Q1 24 | -551.5% | 26.0% |
| Q4 25 | -19.9% | 29.8% | ||
| Q3 25 | -637.8% | 31.1% | ||
| Q2 25 | -203.3% | 23.2% | ||
| Q1 25 | -1077.2% | 28.1% | ||
| Q4 24 | — | 29.1% | ||
| Q3 24 | -785.4% | 25.5% | ||
| Q2 24 | -504.3% | 25.5% | ||
| Q1 24 | -408.0% | 26.0% |
| Q4 25 | $-0.03 | $0.70 | ||
| Q3 25 | $-0.19 | $0.73 | ||
| Q2 25 | $-0.12 | $0.50 | ||
| Q1 25 | $-0.15 | $0.58 | ||
| Q4 24 | — | $0.58 | ||
| Q3 24 | $-0.17 | $0.49 | ||
| Q2 24 | $-0.13 | $0.48 | ||
| Q1 24 | $-0.14 | $0.50 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $128.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $966.9M | $796.4M |
| Total Assets | $1.4B | $7.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $128.5M | — | ||
| Q3 25 | $83.2M | — | ||
| Q2 25 | $92.4M | — | ||
| Q1 25 | $159.3M | — | ||
| Q4 24 | $156.3M | — | ||
| Q3 24 | $126.6M | — | ||
| Q2 24 | $148.3M | — | ||
| Q1 24 | $123.6M | — |
| Q4 25 | $966.9M | $796.4M | ||
| Q3 25 | $964.0M | $779.5M | ||
| Q2 25 | $1.0B | $762.8M | ||
| Q1 25 | $1.0B | $751.5M | ||
| Q4 24 | $1.1B | $732.2M | ||
| Q3 24 | $1.1B | $736.7M | ||
| Q2 24 | $1.1B | $707.1M | ||
| Q1 24 | $1.1B | $703.1M |
| Q4 25 | $1.4B | $7.9B | ||
| Q3 25 | $1.4B | $7.9B | ||
| Q2 25 | $1.4B | $7.9B | ||
| Q1 25 | $1.3B | $7.7B | ||
| Q4 24 | $1.4B | $7.7B | ||
| Q3 24 | $1.4B | $7.7B | ||
| Q2 24 | $1.4B | $7.6B | ||
| Q1 24 | $1.5B | $7.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-34.7M | $206.0M |
| Free Cash FlowOCF − Capex | $-44.6M | $203.7M |
| FCF MarginFCF / Revenue | -99.4% | 286.2% |
| Capex IntensityCapex / Revenue | 21.9% | 3.2% |
| Cash ConversionOCF / Net Profit | — | 9.70× |
| TTM Free Cash FlowTrailing 4 quarters | $-174.1M | $356.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-34.7M | $206.0M | ||
| Q3 25 | $-52.6M | $146.9M | ||
| Q2 25 | $-32.4M | $-19.0M | ||
| Q1 25 | $-11.6M | $25.8M | ||
| Q4 24 | $-108.6M | $52.6M | ||
| Q3 24 | $-28.9M | $6.7M | ||
| Q2 24 | $-30.0M | $2.1M | ||
| Q1 24 | $-41.7M | $30.0M |
| Q4 25 | $-44.6M | $203.7M | ||
| Q3 25 | $-61.5M | $146.4M | ||
| Q2 25 | $-45.8M | $-19.6M | ||
| Q1 25 | $-22.2M | $25.6M | ||
| Q4 24 | $-187.0M | $49.9M | ||
| Q3 24 | $-47.4M | $6.5M | ||
| Q2 24 | $-50.1M | $1.3M | ||
| Q1 24 | $-65.8M | $29.2M |
| Q4 25 | -99.4% | 286.2% | ||
| Q3 25 | -687.0% | 206.3% | ||
| Q2 25 | -267.9% | -30.0% | ||
| Q1 25 | -524.0% | 40.7% | ||
| Q4 24 | -3702.8% | 82.1% | ||
| Q3 24 | -728.4% | 11.1% | ||
| Q2 24 | -683.8% | 2.3% | ||
| Q1 24 | -661.5% | 50.0% |
| Q4 25 | 21.9% | 3.2% | ||
| Q3 25 | 99.7% | 0.8% | ||
| Q2 25 | 78.2% | 0.9% | ||
| Q1 25 | 251.1% | 0.4% | ||
| Q4 24 | 1552.7% | 4.3% | ||
| Q3 24 | 284.6% | 0.4% | ||
| Q2 24 | 274.6% | 1.4% | ||
| Q1 24 | 242.5% | 1.4% |
| Q4 25 | — | 9.70× | ||
| Q3 25 | — | 6.66× | ||
| Q2 25 | — | -1.26× | ||
| Q1 25 | — | 1.46× | ||
| Q4 24 | — | 2.97× | ||
| Q3 24 | — | 0.45× | ||
| Q2 24 | — | 0.14× | ||
| Q1 24 | — | 1.98× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
